Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.

doi:10.1002/onco.13639

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.

The oncologist - 1 Apr 2021

Takeda Masayuki, Takahama Takayuki, Sakai Kazuko, Shimizu Shigeki, Watanabe Satomi, Kawakami Hisato, Tanaka Kaoru, Sato Chihiro, Hayashi Hidetoshi, Nonagase Yoshikane, Yonesaka Kimio, Takegawa Naoki, Okuno Tatsuya, Yoshida Takeshi, Fumita Soichi, Suzuki Shinichiro, Haratani Koji, Saigoh Kazumasa, Ito Akihiko, Mitsudomi Tetsuya, Handa Hisashi, Fukuoka Kazuya, Nakagawa Kazuhiko, Nishio Kazuto

Abstract excerpt

BACKGROUND: Implementation of personalized medicine requires the accessibility of tumor molecular profiling in order to allow prioritization of appropriate targeted therapies for individual patients. Our aim was to study the role of comprehensive genomic profiling assays that may inform treatment recommendations for patients with solid tumors. MATERIALS AND METHODS: We performed a prospective study to evaluate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Genomics and Diagnostics

Share to Cancer Immunotherapy and Biomarkers

Share to High-Throughput Nucleotide Sequencing

Share to Japan

Share to Lung Cancer Treatments and Mutations

Share to Mutation

Share to Neoplasm Recurrence, Local

Source

Open in PubMed Open full text

Identifiers

PMID: 33325566
DOI: 10.1002/onco.13639
PMCID: PMC8018334

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.PMID 33325566Read ↗

Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.Semantic proximity Read ↗

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.Semantic proximity Read ↗

A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers.Semantic proximity Read ↗

Assessing the Impact of Comprehensive Genomic Profiling on Therapeutic Selection for Advanced Solid Tumors in PortugalSemantic proximity Read ↗

First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.Semantic proximity Read ↗

Comprehensive genomic profiling for patients with chemotherapy‐naïve advanced cancerSemantic proximity Read ↗

Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.Semantic proximity Read ↗

Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.Semantic proximity Read ↗

Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice.Semantic proximity Read ↗

Prognostic impact of genomically matched therapy for solid cancers using real-world data from a provincial hospital in JapanSemantic proximity Read ↗

[Clinical Utility of Comprehensive Genome Profiling Using FoundationOne CDx in Japanese Population(PROFILE-F Study)].Semantic proximity Read ↗

Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.